Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes

Dimethyl fumarate (DMF) has emerged as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS). This treatment, however, has been limited by adverse effects, which has prompted development of novel derivatives with improved tolerability. We compared the effects of fumarates on gene expression in astrocytes. Our analysis included diroximel fumarate (DRF) and its metabolite monomethyl fumarate (MMF), along with a novel compound isosorbide di-(methyl fumarate) (IDMF). Treatment with IDMF resulted in the largest number of differentially expressed genes. The effects of DRF and MMF were consistent with NRF2 activation and NF-kappa B inhibition, respectively. IDMF responses, however, were concordant with both NRF2 activation and NF-kappa B inhibition, and we confirmed IDMF-mediated NF-kappa B inhibition using a reporter assay. IDMF also down-regulated IRF1 expression and IDMF-decreased gene promoters were enriched with IRF1 recognition sequences. Genes altered by each fumarate overlapped significantly with those near loci from MS genetic association studies, but IDMF had the strongest overall effect on MS-associated genes. These results show that next-generation fumarates, such as DRF and IDMF, have effects differing from those of the MMF metabolite. Our findings support a model in which IDMF attenuates oxidative stress via NRF2 activation, with suppression of NF-kappa B and IRF1 contributing to mitigation of inflammation and pyroptosis.

Automated summary

Dimethyl fumarate (DMF) is commonly used for treating RRMS but has adverse effects. To improve tolerability, novel derivatives have been developed. In this study, the effects of fumarates on gene expression in astrocytes were compared, and it was found that IDMF had the greatest impact on gene expression, inhibiting NF-kappa B and IRF1 expression, thus reducing inflammation and pyroptosis.